Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft […]
Topline data expected within two months Blinded, interim data to be presented at the Undersea & Hyperbaric Medical Society’s Annual Scientific Meeting in May 2022 CHARLOTTESVILLE, Va., April 11, 2022 — Diffusion Pharmaceuticals Inc. (NASDAQ: […]
Prototype medical device engineered to deliver sustained, sub-psychedelic quantities of candidate DMT-analogues In vitro, time dependent drug elution profile evaluated for three candidate molecules Biocompatibility of drug-loaded medical device demonstrates cell-based safety at doses anticipated […]
Manufacturing Contract with the Toronto Institute of Pharmaceutical Technology VANCOUVER, BC, April 7, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics […]
Committed to the ‘pipeline-in-a-pill’ approach with PD-001 for certain cancers and COVID-19 Advances cGMP manufacturing of clinical drug supply with Southwest Research Institute Receives final positive data for recently conducted prostate cancer model and evaluates […]
Additionally, data associated with the GeneStrat® ddPCR™ and Genestrat NGS™ blood tests will be presented at the American Association for Cancer Research (AACR) BOULDER, Colo., March 29, 2022–Biodesix, Inc. (NASDAQ: BDSX), a leading data-driven diagnostic solutions company with […]
VANCOUVER, BC, March 23, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce […]
VANCOUVER, BC, Feb. 16, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce […]
JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical conditions Clarus expects to announce results from the trial in […]
Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inhibitors, and a next-generation kinase inhibitor platform On […]
Interim results show that oral cepharanthine plus cabazitaxel (combination therapy) significantly reduced tumor volume and increased tumor growth inhibition at day 21, the final day of dosing Dose range findings demonstrate that oral cepharanthine-alone was […]
SALT LAKE CITY, Feb. 17, 2022 / — PolarityTE, Inc. (NASDAQ: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Trademark Office (USPTO) recently issued a Notice of Allowance for U.S. Application […]
HAMILTON, Ontario, Feb. 15, 2022 — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare […]
HAMILTON, Ontario, Feb. 09, 2022 — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare […]
Reliq Health Technologies (TSX.V: RHT) (OTC: RQHTF) NEXT SUPER STOCK livestream 1/27/2022 Reliq Health Technologies (TSX.V: RHT) (OTC: RQHTF) NEXT SUPER STOCK livestream 1/5/2022 Reliq Health Technologies (TSX.V: RHT) (OTC: RQHTF) NEXT SUPER STOCK live! […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
